ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Health Technology

Lupin Ltd.

Company Background

Lupin is a major generic drugmaker that conducts business in more than 100 countries. Among India's five biggest pharmaceuticals, it has about 10 production bases in India and exports generic drugs to other countries.

It was founded in 1968 by Desh Bandhu Gupta, a researcher at a science university. Since the early 2000s, it has been actively buying companies in South Africa, Mexico, even Japan.

It got a head start on its Indian competitors by building a supply network in Japan. It did so in 2007 by acquiring Kyowa Pharmaceutical Industry, an Osaka-based medium-size generic drugmaker. In 2014, it set up a venture with Yoshindo, a generic drug company based in Japan's Toyama Prefecture, to jointly develop generic biomedicines.

Zyma Laboratories, an affiliate company run by Desh Bandhu Gupta and other executives, is Lupin's top shareholder; the founding family still owns some shares in Lupin.

Business Summary

Lupin Ltd. engages in the manufacture of pharmaceutical products. It offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2020 INRUSD
Revenue151,619.10M2,138.31M
Gross Profit41,517.40M585.52M
Operating income12,171.10M171.65M
Income before tax7,532.90M106.23M
Net income-3,994.90M-56.34M
EBITDA21,873.30M308.48M
Diluted EPS-5.95-0.08
Dividends Per Share60.08
Total Assets249,838.50M3,302.50M
Total liabilities123,953.10M1,638.48M
Total equity125,357.80M1,657.04M
Operating cash flow12,562.80M177.17M
Currency in INRCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 137,818.50M 170,090.50M 155,509.10M 144,095.60M 151,619.10M
Gross Profit 67,159.10M 83,802.20M 60,769.20M 41,652.90M 41,517.40M
Operating income 32,615.50M 33,543.30M 18,628.40M 15,088.80M 12,171.10M
Income before tax 33,239.40M 35,348.90M 5,432.90M 14,052.10M 7,532.90M
Net income 22,607.40M 25,574.60M 2,512.60M 5,120.90M -3,994.90M
EBITDA 37,486.80M 42,665.60M 30,899.40M 23,549.30M 21,873.30M
Diluted EPS 49.93 56.46 5.54 13.35 -5.95
Dividends Per Share 7.50 7.50 5 5 6
Total Assets 226,248.60M 266,072.80M 263,053.80M 279,493.70M 249,838.50M
Total liabilities 114,294.10M 130,751.90M 126,882.40M 141,602.80M 123,953.10M
Total equity 111,624.50M 134,966.50M 135,761.40M 137,413.10M 125,357.80M
Operating cash flow -4,269.70M 40,092.80M 15,901M 14,897.10M 12,562.80M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 2,105.03M 2,536.50M 2,412.26M 2,060.19M 2,138.31M
Gross Profit 1,025.78M 1,249.71M 942.65M 595.52M 585.52M
Operating income 498.16M 500.22M 288.96M 215.73M 171.65M
Income before tax 507.69M 527.14M 84.27M 200.90M 106.23M
Net income 345.30M 381.38M 38.97M 73.21M -56.34M
EBITDA 572.57M 636.25M 479.31M 336.69M 308.48M
Diluted EPS 0.76 0.84 0.08 0.19 -0.08
Dividends Per Share 0.11 0.11 0.07 0.07 0.08
Total Assets 3,416.49M 4,097.52M 4,033.22M 4,034.55M 3,302.50M
Total liabilities 1,725.91M 2,013.58M 1,945.40M 2,044.06M 1,638.48M
Total equity 1,685.59M 2,078.48M 2,081.53M 1,983.58M 1,657.04M
Operating cash flow -65.21M 597.89M 246.65M 212.99M 177.17M

Valuation Measures

Mar 2020
PER--
ROA-1.50%
ROE-3.04%
Operating margin8.02%
Profit margin-2.63%

Key executives

  • Chief Executive Officer & Executive Director: Vinita D. Gupta
  • CFO, Executive Director & Head-Corporate Affairs: Ramesh Swaminathan
  • CEO-US Generics, Global Head-R&D: Alok Sonig
  • Executive Vice President-Medical Research: Dhananjay Bakhle
  • Executive Director & Managing Director: Nilesh Deshbandhu Gupta

Shareholders

  • Lupin Investments Pvt Ltd. (45.3%)
  • Life Insurance Corp of India (3.7%)
  • HDFC Asset Management Co. Ltd. (Invt Mgmt) (3.5%)
  • Comgest SA (1.8%)
  • SBI Funds Management Pvt Ltd. (1.7%)
  • The Vanguard Group, Inc. (1.7%)
  • JHUNJHUNWALA RAKESH RADHESHYAM (1.4%)
  • Franklin Templeton Asset Management (India) Pvt Ltd. (1.3%)
  • Norges Bank Investment Management (1.3%)
  • Nippon Life India Asset Management Ltd. (Invt Mgmt) (1.2%)

Contact Details

  • Website:http://www.lupin.com
  • Address: B/4 Laxmi Towers, Bandra Kurla Complex, Mumbai, 400051, India
  • Phone: +91.22.66402222

Related Companies

  • Lupin Europe GmbH LLC
  • Lupin Japan & Asia Pacific KK
  • Lupin Latam, Inc.
  • Lupin Pharma LLC
  • Medquimica Industria Farmaceutica
  • Lupin Middle East FZ LLC
  • Generic Health Sdn. Bhd.
  • Lupin Philippines, Inc
  • Bellwether Pharma Pty Ltd.
  • Lupin Mexico SA de CV
  • Lupin Pharma Canada Ltd.
  • Lupin Holdings BV
  • Lupin Management, Inc.
  • Lupin Research, Inc.
  • Lupin, Inc.
  • VeeGo Pharma LLC
  • Lupin Atlantis Holdings SA
  • Lupin Farmaceutica Do Brasil Ltda.
  • Lupin Pharmaceuticals Ltd/Brazil/
  • Lupin Employees Benefit Trust
  • Nanomi BV
  • Lupin Healthcare Ltd.
  • Gavis Pharmaceuticals LLC
  • Lupin Chemical (Thailand) Ltd.
  • Lupin Australia Pty Ltd.
  • Lupin Holdings B.V., Netherlands
  • Polynova Industries Ltd.
  • Lupin Laboratories Ltd.
  • Laboratorios Grin SA de CV
  • Lupin Pharmaceuticals, Inc.

Competitors

  • Amneal Pharmaceuticals, Inc. Class A
  • Aurobindo Pharma Ltd
  • Teva Pharmaceutical Industries Limited
  • Cadila Healthcare Limited
  • Dr. Reddy's Laboratories Ltd.
  • Amneal Pharmaceuticals, Inc. Class A
  • Perrigo Co. Plc
  • Midatech Pharma Plc
  • Dare Bioscience, Inc.
  • Agile Therapeutics, Inc.
  • Bora Pharmaceuticals Co Ltd
  • TherapeuticsMD, Inc.
Last Updated on 27 Nov, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more